Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center

被引：0
|
作者：
Michael D. Nailor
Kellie J. Goodlet
Omar Gonzalez
J. Tyler Haller
机构：
[1] St. Joseph’s Hospital and Medical Center,Department of Pharmacy Services
[2] Midwestern University College of Pharmacy,Department of Pharmacy Practice
[3] Arizona Pulmonary Specialists,Infectious Disease Division
[4] Barrow Neurological Institute,undefined
[5] St. Joseph Hospital and Medical Center,undefined
来源：
CNS Drugs | 2024年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：225 / 229
页数：4
相关论文
共 50 条
  • [41] Impact of the Administration of Liposomal Amphotericin B in Patients with Renal Function Impairment at Initiation of Treatment
    Alvarez-Lerma, Francisco
    Munoz-Bermudez, Rosana
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2016, 29 : 17 - 19
  • [42] Optimization of the manufacturing process of a complex amphotericin B liposomal formulation using quality by design approach
    Liu, Huolong
    Rivnay, Benjamin
    Avery, Ken
    Myung, Ja Hye
    Kozak, Darby
    Landrau, Nelson
    Nivorozhkin, Alex
    Ashraf, Muhammad
    Yoon, Seongkyu
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 585
  • [43] Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients
    Bohme, A
    Hoelzer, D
    MYCOSES, 1996, 39 (11-12) : 419 - 426
  • [44] Use of a liposomal formulation of amphotericin B for treating wound aspergillosis in a goliath heron (Ardea goliath)
    Bonar, CJ
    Lewandowski, AH
    JOURNAL OF AVIAN MEDICINE AND SURGERY, 2004, 18 (03) : 162 - 166
  • [45] TOLERANCE OF HIGH-DOSES OF AMPHOTERICIN-B BY INFUSION OF A LIPOSOMAL FORMULATION IN CHILDREN WITH CANCER
    EMMINGER, W
    GRANINGER, W
    EMMINGERSCHMIDMEIER, W
    ZOUBEK, A
    PILLWEIN, K
    SUSANI, M
    WASSERER, A
    GADNER, H
    ANNALS OF HEMATOLOGY, 1994, 68 (01) : 27 - 31
  • [46] Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients
    Walsh, TJ
    Yeldandi, V
    McEvoy, M
    Gonzalez, C
    Chanock, S
    Freifeld, A
    Seibel, NI
    Whitcomb, PO
    Jarosinski, P
    Boswell, G
    Bekersky, I
    Alak, A
    Buell, D
    Barret, J
    Wilson, W
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) : 2391 - 2398
  • [47] In vitro in vivo relations for the parenteral liposomal formulation of Amphotericin B: A biorelevant and clinically relevant approach
    de Leon-Ortega, R. Diaz
    D'Arcy, D. M.
    Lamprou, D. A.
    Xue, W. F.
    Fotaki, N.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2021, 159 : 188 - 197
  • [48] Comparison of Early Fungicidal Activity and Mortality Between Daily Liposomal Amphotericin B and Daily Amphotericin B Deoxycholate for Cryptococcal Meningitis
    Kimuda, Sarah
    Kwizera, Richard
    Dai, Biyue
    Kigozi, Enos
    Kasozi, Derrick
    Rutakingirwa, Morris K.
    Tukundane, Asmus
    Shifah, Nabbaale
    Luggya, Tony
    Luswata, Andrew
    Ndyetukira, Jane Frances
    Yueh, Spencer L.
    Mulwana, Suzan
    Wele, Abduljewad
    Bahr, Nathan C.
    Meya, David B.
    Boulware, David R.
    Skipper, Caleb P.
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [49] Efficacy of intrathecal liposomal amphotericin B plus oral posaconazole in the treatment of acute meningeal cryptococcosis in a murine model
    Capilla, Javier
    Flavia, Alexandra
    Mayayo, Emilio
    Guarro, Josep
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (03) : 282 - 283
  • [50] Liposomal Amphotericin B and HIV-Associated Visceral LeishmaniasisConcerns about Nephrotoxicity and Administration Schedule
    Sergio Sabbatani
    Roberto Manfredi
    Ginevra Marinacci
    Michele Pavoni
    Michele Nafissi
    Francesco Chiodo
    Clinical Drug Investigation, 2005, 25 : 85 - 87
12345